Short answer
ARTIVION, INC. (AORT) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Third-quarter results for the period ended September 30, 2026 announced on November 5, 2026.
ARTIVION, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Third-quarter results for the period ended September 30, 2026 announced on November 5, 2026
- Detailed financial performance and management commentary available in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $123.8M, up 9% constant currency, led by On-X growth 13% and aortic stent grafts growth 12%
- GAAP net loss $(7.9)M, or $(0.16) per share, versus $6.5M profit and $0.13 per share
- Adjusted EBITDA $22.5M, down 8%, signaling weaker operating leverage despite revenue growth
- Free cash flow $(36.4)M through nine months, with $116.7M Endospan acquisition spending and $31.8M capital expenditures
- 2026 outlook narrowed to revenue $484M-$492M and adjusted EBITDA $93M-$98M, including approximately $8M Endospan-related expense
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ARTIVION, INC. 8-K filings
Get the next AORT 8-K as it lands
Follow AORT for push alerts, or ask the research agent what this filing means.